A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Subscribe To Our Newsletter & Stay Updated
